Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?

Jennifer S. Li, Katherine Berezny, Rakhi Kilaru, Lydie Hazan, Ronald Portman, Ronald Hogg, Randall Jenkins, Prapti Kanani, Carol M. Cottrill, Tej K. Mattoo, Ludmila Zharkova, Ludmila Kozlova, Irit Weisman, David Deitchman, Robert M. Califf

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We evaluated the efficacy, safety, and dose-response relationship of fosinopril in children aged 6 to 16 years with hypertension or high-normal blood pressure with an associated medical condition requiring treatment. The study was a prospective, double-blind, placebo-controlled trial conducted in 78 clinical sites in the United States, Russia, and Israel. There were 4 phases: a screening phase of 10 days maximum, a 4-week dose-response phase, a placebo withdrawal phase of 2 weeks maximum, and a 52-week open-label safety phase. The primary objective of the dose-response phase was to determine whether low (0.1 mg/kg), medium (0.3 mg/kg), or high (0.6 mg/kg) doses of fosinopril based on established adult dosing affect trough seated systolic blood pressure. During the dose-response phase, all 3 doses were equally effective in lowering systolic blood pressure. During the placebo withdrawal phase, there was an adjusted mean systolic blood pressure increase of 5.2 mm Hg for the placebo group and 1.5 mm Hg for the fosinopril group, a net withdrawal effect of 3.7 mm Hg (P=0.013). Fosinopril was well tolerated; serious adverse events occurred infrequently and were generally not attributed to fosinopril. Because children appear to be more sensitive to lower doses of fosinopril than adults, starting doses for children should be ≤0.1 mg/kg.

Original languageEnglish (US)
Pages (from-to)289-293
Number of pages5
JournalHypertension
Volume44
Issue number3
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Fosinopril
Blood Pressure
Placebos
Hypertension
Safety
Russia
Israel

Keywords

  • Blood pressure
  • Children
  • Fosinopril
  • Hypertension, arterial

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Li, J. S., Berezny, K., Kilaru, R., Hazan, L., Portman, R., Hogg, R., ... Califf, R. M. (2004). Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension, 44(3), 289-293. https://doi.org/10.1161/01.HYP.0000138069.68413.f0

Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? / Li, Jennifer S.; Berezny, Katherine; Kilaru, Rakhi; Hazan, Lydie; Portman, Ronald; Hogg, Ronald; Jenkins, Randall; Kanani, Prapti; Cottrill, Carol M.; Mattoo, Tej K.; Zharkova, Ludmila; Kozlova, Ludmila; Weisman, Irit; Deitchman, David; Califf, Robert M.

In: Hypertension, Vol. 44, No. 3, 09.2004, p. 289-293.

Research output: Contribution to journalArticle

Li, JS, Berezny, K, Kilaru, R, Hazan, L, Portman, R, Hogg, R, Jenkins, R, Kanani, P, Cottrill, CM, Mattoo, TK, Zharkova, L, Kozlova, L, Weisman, I, Deitchman, D & Califf, RM 2004, 'Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?', Hypertension, vol. 44, no. 3, pp. 289-293. https://doi.org/10.1161/01.HYP.0000138069.68413.f0
Li, Jennifer S. ; Berezny, Katherine ; Kilaru, Rakhi ; Hazan, Lydie ; Portman, Ronald ; Hogg, Ronald ; Jenkins, Randall ; Kanani, Prapti ; Cottrill, Carol M. ; Mattoo, Tej K. ; Zharkova, Ludmila ; Kozlova, Ludmila ; Weisman, Irit ; Deitchman, David ; Califf, Robert M. / Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?. In: Hypertension. 2004 ; Vol. 44, No. 3. pp. 289-293.
@article{b484934f999744638fdf809898c0ad05,
title = "Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?",
abstract = "We evaluated the efficacy, safety, and dose-response relationship of fosinopril in children aged 6 to 16 years with hypertension or high-normal blood pressure with an associated medical condition requiring treatment. The study was a prospective, double-blind, placebo-controlled trial conducted in 78 clinical sites in the United States, Russia, and Israel. There were 4 phases: a screening phase of 10 days maximum, a 4-week dose-response phase, a placebo withdrawal phase of 2 weeks maximum, and a 52-week open-label safety phase. The primary objective of the dose-response phase was to determine whether low (0.1 mg/kg), medium (0.3 mg/kg), or high (0.6 mg/kg) doses of fosinopril based on established adult dosing affect trough seated systolic blood pressure. During the dose-response phase, all 3 doses were equally effective in lowering systolic blood pressure. During the placebo withdrawal phase, there was an adjusted mean systolic blood pressure increase of 5.2 mm Hg for the placebo group and 1.5 mm Hg for the fosinopril group, a net withdrawal effect of 3.7 mm Hg (P=0.013). Fosinopril was well tolerated; serious adverse events occurred infrequently and were generally not attributed to fosinopril. Because children appear to be more sensitive to lower doses of fosinopril than adults, starting doses for children should be ≤0.1 mg/kg.",
keywords = "Blood pressure, Children, Fosinopril, Hypertension, arterial",
author = "Li, {Jennifer S.} and Katherine Berezny and Rakhi Kilaru and Lydie Hazan and Ronald Portman and Ronald Hogg and Randall Jenkins and Prapti Kanani and Cottrill, {Carol M.} and Mattoo, {Tej K.} and Ludmila Zharkova and Ludmila Kozlova and Irit Weisman and David Deitchman and Califf, {Robert M.}",
year = "2004",
month = "9",
doi = "10.1161/01.HYP.0000138069.68413.f0",
language = "English (US)",
volume = "44",
pages = "289--293",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?

AU - Li, Jennifer S.

AU - Berezny, Katherine

AU - Kilaru, Rakhi

AU - Hazan, Lydie

AU - Portman, Ronald

AU - Hogg, Ronald

AU - Jenkins, Randall

AU - Kanani, Prapti

AU - Cottrill, Carol M.

AU - Mattoo, Tej K.

AU - Zharkova, Ludmila

AU - Kozlova, Ludmila

AU - Weisman, Irit

AU - Deitchman, David

AU - Califf, Robert M.

PY - 2004/9

Y1 - 2004/9

N2 - We evaluated the efficacy, safety, and dose-response relationship of fosinopril in children aged 6 to 16 years with hypertension or high-normal blood pressure with an associated medical condition requiring treatment. The study was a prospective, double-blind, placebo-controlled trial conducted in 78 clinical sites in the United States, Russia, and Israel. There were 4 phases: a screening phase of 10 days maximum, a 4-week dose-response phase, a placebo withdrawal phase of 2 weeks maximum, and a 52-week open-label safety phase. The primary objective of the dose-response phase was to determine whether low (0.1 mg/kg), medium (0.3 mg/kg), or high (0.6 mg/kg) doses of fosinopril based on established adult dosing affect trough seated systolic blood pressure. During the dose-response phase, all 3 doses were equally effective in lowering systolic blood pressure. During the placebo withdrawal phase, there was an adjusted mean systolic blood pressure increase of 5.2 mm Hg for the placebo group and 1.5 mm Hg for the fosinopril group, a net withdrawal effect of 3.7 mm Hg (P=0.013). Fosinopril was well tolerated; serious adverse events occurred infrequently and were generally not attributed to fosinopril. Because children appear to be more sensitive to lower doses of fosinopril than adults, starting doses for children should be ≤0.1 mg/kg.

AB - We evaluated the efficacy, safety, and dose-response relationship of fosinopril in children aged 6 to 16 years with hypertension or high-normal blood pressure with an associated medical condition requiring treatment. The study was a prospective, double-blind, placebo-controlled trial conducted in 78 clinical sites in the United States, Russia, and Israel. There were 4 phases: a screening phase of 10 days maximum, a 4-week dose-response phase, a placebo withdrawal phase of 2 weeks maximum, and a 52-week open-label safety phase. The primary objective of the dose-response phase was to determine whether low (0.1 mg/kg), medium (0.3 mg/kg), or high (0.6 mg/kg) doses of fosinopril based on established adult dosing affect trough seated systolic blood pressure. During the dose-response phase, all 3 doses were equally effective in lowering systolic blood pressure. During the placebo withdrawal phase, there was an adjusted mean systolic blood pressure increase of 5.2 mm Hg for the placebo group and 1.5 mm Hg for the fosinopril group, a net withdrawal effect of 3.7 mm Hg (P=0.013). Fosinopril was well tolerated; serious adverse events occurred infrequently and were generally not attributed to fosinopril. Because children appear to be more sensitive to lower doses of fosinopril than adults, starting doses for children should be ≤0.1 mg/kg.

KW - Blood pressure

KW - Children

KW - Fosinopril

KW - Hypertension, arterial

UR - http://www.scopus.com/inward/record.url?scp=4444349617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444349617&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000138069.68413.f0

DO - 10.1161/01.HYP.0000138069.68413.f0

M3 - Article

C2 - 15262902

AN - SCOPUS:4444349617

VL - 44

SP - 289

EP - 293

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3

ER -